Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HealthEquity, Inc. filings document regulatory disclosures for an HSA custodian and consumer-directed benefits administrator. Recent 8-K reports cover operating results and financial condition, guidance furnished under Regulation FD, HSA account and asset metrics, revenue categories, stock repurchase activity, and hedging used to reduce HSA cash repricing risk.
Governance filings record board appointments and committee assignments, annual meeting vote results, auditor ratification, advisory executive compensation votes, executive employment agreement amendments, severance arrangements, equity award terms, and technology-organization leadership responsibility. These disclosures frame the company's capital allocation, compensation governance, risk oversight and public-company reporting obligations.
HEALTHEQUITY, INC. reported that EVP & CFO James M. Lucania acquired 27,283 shares of common stock through a grant/award at no purchase price. These are restricted stock units, each representing one share. The award vests 25% on April 1, 2027, then 6.25% quarterly over the following twelve quarters. After this compensation grant, he directly holds 111,849 shares.
Cutler Scott reported acquisition or exercise transactions in this Form 4 filing.
HealthEquity, Inc. President and CEO Scott Cutler received an equity grant of 72,754 shares of common stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share because it is compensation, not an open‑market purchase.
Each unit represents a contingent right to one share of common stock. The grant will vest over time, with 25% vesting on April 1, 2027, and 6.25% vesting on the first day of each calendar quarter for the following twelve quarters. After this grant, Cutler directly holds 182,574 shares of common stock, reflecting both existing ownership and the newly awarded units as reported.
HealthEquity Inc: Amendment No. 9 to a Schedule 13G/A was filed by The Vanguard Group reporting beneficial ownership of 0 shares of common stock, representing 0% of the class. The filing notes an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, with certain Vanguard subsidiaries to report ownership separately.
HealthEquity, Inc. files its annual report highlighting its role as a leading U.S. provider of technology-enabled health savings and consumer-directed benefits. As of January 31, 2026, it administered 10.6 million HSAs with $36.5 billion in HSA Assets and 7.2 million complementary CDBs, totaling 17.8 million accounts.
The company generates revenue from service, custodial, and interchange fees, with custodial fees from HSA cash and Client-held funds contributing 48% of revenue in fiscal 2026. A 2025 acquisition of the BenefitWallet HSA portfolio added about 616,000 HSAs and $2.7 billion of HSA Assets for $425 million.
HealthEquity emphasizes proprietary cloud-based platforms, integrated partnerships with more than 200 Network Partners, and increasing use of AI tools. Key risks include reliance on tax advantages for HSAs, interest-rate sensitivity, partner and cybersecurity failures, growing fraud and ransomware threats, intense competition from large financial and healthcare firms, and evolving privacy, healthcare, and AI regulation.
HealthEquity, Inc. reported record results for the fiscal year and fourth quarter ended January 31, 2026 and raised its fiscal 2027 outlook. Full-year revenue rose 9% to $1.31 billion, while net income more than doubled to $215.2 million, lifting net margin to 16% from 8%. Adjusted EBITDA grew 20% to $566.0 million, with margin improving to 43%.
Fourth-quarter revenue increased 7% to $334.6 million, and net income rose 89% to $49.7 million. Adjusted EBITDA for the quarter was $132.9 million, up 23%, with margin expanding to 40%. Total HSA Assets reached $36.5 billion, up 14%, and total accounts were 17.8 million.
The company returned $301.7 million to shareholders via repurchases and ended the year with $318.9 million in cash and $957.4 million of debt. For fiscal 2027, it guides revenue to $1.405–$1.415 billion, GAAP net income of $239–$246 million, non-GAAP net income of $392–$400 million, and Adjusted EBITDA of $618–$628 million.
HealthEquity, Inc. reported strong operating metrics for its fiscal year ended January 31, 2026, highlighted by a record fourth quarter for new health savings accounts (HSAs). HSAs reached 10.6 million, up 7% from 9.9 million a year earlier, and Total Accounts grew 4% to 17.8 million. HSA Assets rose 14% to $36.5 billion, with HSA investments increasing 26% year over year to $18.5 billion, reflecting greater use of investment options. The company reaffirmed its outlook for fiscal 2026 and 2027 and stated that fiscal 2026 results should be near the top of prior guidance ranges. HealthEquity also outlined a schedule for repricing $17.3 billion of HSA cash through 2030 and announced the date and time of its March 17, 2026 earnings call and upcoming investor conference appearances.
HealthEquity, Inc. director Parker Stuart B. reported receiving 1,263 shares of common stock on February 2, 2026 at a price of $0 per share, reflecting the vesting of restricted stock units. After this award, he directly holds 23,098 shares of HealthEquity common stock.
The footnote explains that each restricted stock unit equals one common share. Of this award, 316 shares vested on February 2, 2026, with an additional 316 shares each scheduled to vest on May 1 and August 1, 2026, and the remaining 315 shares vesting on November 1, 2026. Vested shares will be delivered to him upon the earlier of a change in control of HealthEquity, the end of his service, or his death.
HealthEquity, Inc. director Rajesh Natarajan reported an equity award in the form of restricted stock units that delivered 976 shares of common stock on February 2, 2026 at a price of $0 per share. Following this transaction, he beneficially owned 15,253 shares directly.
Each restricted stock unit represents a right to receive one share of HealthEquity common stock. The units vested as to 244 shares on February 2, 2026 and are scheduled to vest as to 244 shares each on the first day of May, August, and November of 2026. Vested shares will be delivered to Natarajan on the earlier of February 1, 2033, a change of control of HealthEquity as defined in the 2024 equity incentive plan, his termination of service under that plan, or his death.
HealthEquity, Inc. insider activity: President and CEO Scott Cutler, who also serves as a director of HealthEquity, Inc. (HQY), reported a disposition of common stock. On 01/12/2026, he disposed of 12,496 shares of common stock at a price of $89.8274 per share, as shown by transaction code "F". Following this transaction, he directly beneficially owned 109,820 shares of HealthEquity common stock.
A holder of common stock of the issuer has filed a notice of proposed sale covering 12,496 shares, to be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/12/2026. The filing lists an aggregate market value of 1122483.19 for these shares and notes that 85,436,286 shares of the same class are outstanding.
The shares to be sold were acquired as restricted stock vesting on 01/06/2025 directly from the issuer as compensation, in an amount matching the proposed sale of 12,496 shares. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.